Debate

Low-dose stavudine trials: a public health priority for developing countries

W D Francois Venter, Steve Innes, Mark Cotton
Southern African Journal of HIV Medicine | Vol 13, No 1 | a154 | DOI: https://doi.org/10.4102/sajhivmed.v13i1.154 | © 2012 W D Francois Venter, Steve Innes, Mark Cotton | This work is licensed under CC Attribution 4.0
Submitted: 15 December 2012 | Published: 13 March 2012

About the author(s)

W D Francois Venter, Wits Reproductive Health and HIV Institute (WRHI), Department of Medicine, University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
Steve Innes, Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children’s Hospital and Stellenbosch University, Western Cape, South Africa
Mark Cotton, Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children’s Hospital and Stellenbosch University, Western Cape, South Africa


Share this article

Bookmark and Share

Abstract

The debate around relooking at stavudine dosing, both in terms of the adult low-dose stavudine study and more broadly, is welcome. The study being proposed to evaluate low-dose stavudine v. tenofovir is a fairly standard placebo-controlled non-inferiority study. The study design is not controversial; however, the choice of study drug has attracted critical attention.

Keywords

No related keywords in the metadata.

Metrics

Total abstract views: 1540
Total article views: 2343

 

Crossref Citations

1. Mass spectrometric investigations into the brain delivery of abacavir, stavudine and didanosine in a rodent model
Sipho Mdanda, Sphamandla Ntshangase, Sanil D. Singh, Tricia Naicker, Hendrik G. Kruger, Sooraj Baijnath, Thavendran Govender
Xenobiotica  vol: 50  issue: 5  first page: 570  year: 2020  
doi: 10.1080/00498254.2019.1655605